About US
Contact us
-
J&J braces for biosim attack after losing last-ditch Remicade patent fightJohnson & Johnson lost its court battle to shieldRemicade from encroaching biosimilar competition. A U.S. District Judge on Wednesdaystruck down a key patent on the drug, clearing the way for Cell2016/9/1
-
Boehringer and Saniona to develop new compounds for schizophrenia treatmentGerman company Boehringer Ingelheim and Denmark-based biotech company Saniona have partnered to discover and develop new compounds for the treatment of schizophrenia. After signing the agreement, San2016/8/31
-
UK scientists identify new technique for early diagnosis of Parkinson's diseaseScientists at the University of Edinburgh have identified a new way to detect Parkinson's disease in the early stages of illness. Parkinson’s disease is a progressive brain condition caused by the lo2016/8/31
-
Boehringer Ingelheim, Duke Clinical Research Institute expand collaboration on IPF studyBoehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create thelargest patient registry for Idiopathic Pulmonary Fibrosis (IPF). IPF is a2016/8/30
-
Deals this week: Cell Medica Limited, Cloaked Therapeutics, SynCore BiotechCell Medica Limitedand University College London (UCL) have entered a research collaboration agreement to develop leading-edge modified T-cell receptor (TCR) products for the treatment of cancer. Acc2016/8/30
-
Eisai’s anticancer agent approved for additional indication of CLL in JapanEisai’s anticancer agent treakisym for injection 100mg has received approval for an additional indication of chronic lymphocytic leukaemia (CLL) in Japan. CLL is a blood cancer that is characterised2016/8/29
-
Johns Hopkins Medicine opens new Zika virus treatment and research centreJohns Hopkins Medicine has opened a new centre to provide comprehensive care to patients infected with theZika virus. The Wilmer Eye Institute, which treats eye concerns associated with Zika virus, l2016/8/29
-
Join AtoZ-Cro at Marcus Evans Event in GermanyAtoZ-CRO will be attending Marcus Evans event in Cologne, Germany. The 14th annual Evolution Summit is the premium forum bringing elite buyers and sellers together. As an invitation-only event taking2016/8/26
-
Report: Unmet need for safer anti-arrhythmic drugs in atrial fibrillation market to continue through to 2025Unavailability of safer anti-arrhythmic drugs is expected to be major issue in the atrial fibrillation market, according to a new report from GlobalData. Titled 'PharmaPoint: Atrial Fibrillation – Gl2016/8/26
-
BARDA contracts SAB Biotherapeutics to advance MERS treatmentThe US Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) has awardeda $5.3m contract to US-based SAB Biotherapeuticsfor theadvancement offir2016/8/25